Table 2.
Characteristics of the patients after propensity score matching.
| Variables | Sorafenib (n = 42) | Lenvatinib (n = 42) | P value | Standardized difference |
| Age (yr) | 70.0 (63.0–79.0) | 70.0 (65.0–76.0) | .893 | 0.000 |
| Sex (male/female) | 33/9 | 34/8 | .785 | 0.060 |
| BMI (kg/m2) | 21.45 (19.30–24.20) | 22.85 (21.10–24.70) | .128 | 0.041 |
| Diabetes mellitus (yes/no) | 10/32 | 10/32 | 1.000 | 0.000 |
| Hypertension (yes/no) | 25/17 | 26/16 | .823 | 0.049 |
| Pretreatment diuretics use (yes/no) | 11/31 | 7/35 | .287 | 0.233 |
| Diuretics addition or increase during treatment (yes/no) | 4/38 | 7/35 | .331 | 0.215 |
| Etiology (HBV/HCV/NBNC) | 11/14/17 | 14/10/18 | .833 | 0.049 |
| Performance status 0 (yes/no) | 33/9 | 32/10 | .794 | 0.057 |
| Child-Pugh class (A/B) | 35/7 | 35/7 | 1.000 | 0.000 |
| BCLC stage (B/C) | 15/27 | 17/25 | .653 | 0.099 |
| Platelet count (×104/μL) | 13.30 (9.20–18.50) | 16.30 (10.60–20.50) | .168 | 0.220 |
| PT (%) | 83.0 (72.0–95.0) | 88.5 (83.0–96.0) | .081 | 0.362 |
| T.bil (mg/dL) | 0.80 (0.60–1.10) | 0.90 (0.70–1.00) | .967 | 0.153 |
| Albumin (g/dL) | 3.60 (3.20–3.90) | 3.40 (3.10–3.90) | .475 | 0.103 |
| ALT (IU/mL) | 27.0 (17.0–50.0) | 28.0 (17.0–42.0) | .914 | 0.052 |
| AFP (ng/mL) | 109.5 (9.0–1164.0) | 39.5 (5.0–660.0) | .428 | 0.048 |
| Sodium (mEq/l) | 140.0 (139.0–141.0) | 140.0 (138.0–141.0) | .534 | 0.204 |
| BUN (mg/dL) | 15.0 (13.0–17.0) | 12.5 (11.0–18.0) | .171 | 0.182 |
| Creatinine (mg/dL) | 0.800 (0.720–0.900) | 0.805 (0.710–0.890) | .875 | 0.167 |
| eGFR (mL/min/1.73 m2) | 73.30 (62.50–79.70) | 70.90 (61.85–81.70) | .713 | 0.049 |
Data are given as the medians with interquartile range or numbers.
Standardized difference is absolute value.
AFP = alpha fetoprotein, ALT = alanine aminotransferase, BCLC = Barcelona Clinic liver cancer, BMI = body mass index, BUN = blood urea nitrogen, eGFR = estimated glomerular filtration rate, PT = prothrombin, T.bil = total bilirubin.